Feb 26 (Reuters) - CARsgen Therapeutics 2171.HK:
INTRODUCTION OF ZHUHAI SB XINCHUANG TO ACCELERATE ALLOGENEIC CAR-T CELL PRODUCTS DEVELOPMENT IN MAINLAND CHINA
INVESTMENT FUND TO SUBSCRIBE FOR ADDITIONAL REGISTERED CAPITAL OF UCARSGEN BIOTECH FOR RMB80 MILLION
Further company coverage: 2171.HK
((Reuters.Briefs@thomsonreuters.com;))